Earnings Call Summary | Journey Medical(DERM.US) Q1 2024 Earnings Conference
Earnings Call Summary | Journey Medical(DERM.US) Q1 2024 Earnings Conference
The following is a summary of the Journey Medical Corporation (DERM) Q1 2024 Earnings Call Transcript:
以下是Journey Medical Corporation（DERM）2024年第一季度财报电话会议记录的摘要：
Financial Performance:
财务业绩：
Journey Medical reported Q1 revenue of $13 million, a 7% increase year-over-year, with Qbrexza and Accutane contributing over $10.8 million. The company realized significant reduction in SG&A expenses and achieved profitability in Q1. Over 90% of the company's revenue comes from Qbrexza, Accutane, Amzeeq, and Zilxi. The company's cash resources reached $24.1 million at the end of Q1 2024.
Journey Medical报告称，第一季度收入为1300万美元，同比增长7％，其中Qbrexza和Accutane的收入超过1,080万美元。该公司大幅减少了销售和收购费用，并在第一季度实现了盈利。该公司90％以上的收入来自Qbrexza、Accutane、Amzeeq和Zilxi。截至2024年第一季度末，该公司的现金资源达到2410万美元。
Business Progress:
业务进展：
Qbrexza and Accutane gained market share, expected to drive growth throughout 2024. Journey Medical is preparing to launch DFD-29 for Rosacea treatment following positive Phase 3 trial results. The FDA has accepted the new drug application for DFD-29, with a planned date in November. The company is exploring opportunities to out-license its IP and acquire or in-license FDA-approved products. The company expects net revenues in the range of $55 to $60 million by the year-end.
Qbrexza和Accutane增加了市场份额，预计将推动整个2024年的增长。在 3 期试验结果呈阳性之后，Journey Medical 正准备推出用于酒渣鼻治疗的 DFD-29。美国食品药品管理局已经接受了 DFD-29 的新药申请，计划于11月提交。该公司正在探索向外许可其知识产权以及收购或获得美国食品药品管理局批准的产品许可的机会。该公司预计，到年底，净收入将在5,500万美元至6000万美元之间。
More details: Journey Medical IR
更多详情： 旅程医疗 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。